Location History:
- Headington, GB (2009)
- Oxford, GB (2010 - 2013)
- Birmingham, GB (2009 - 2024)
Company Filing History:
8 out of 263 
1 out of 832,961 Years Active: 2009-2024
Title: Roy Bicknell: Innovator in Angiogenesis Inhibition
Introduction
Roy Bicknell is a prominent inventor based in Birmingham, GB. He has made significant contributions to the field of biomedical research, particularly in the area of angiogenesis inhibition. With a total of 9 patents to his name, Bicknell's work has the potential to impact therapeutic strategies for various diseases.
Latest Patents
Bicknell's latest patents include innovative methods for inhibiting angiogenesis. One notable invention focuses on inhibitors of the interaction between CLEC14A and multimerin-2. This method involves administering an agent that disrupts this interaction, which can be an antibody, polypeptide, peptide, polynucleotide, peptidomimetic, natural product, carbohydrate, aptamer, or small molecule. Another significant patent relates to isolated antibodies that selectively bind to CLEC14A, detailing specific amino acid sequences for heavy and light chain variable regions. These inventions also encompass chimeric antigen receptors and nucleic acid molecules, showcasing Bicknell's commitment to advancing medical science.
Career Highlights
Throughout his career, Roy Bicknell has worked with notable organizations, including Cancer Research Technology Limited. His research has been pivotal in understanding the mechanisms of angiogenesis and developing targeted therapies.
Collaborations
Bicknell has collaborated with esteemed colleagues such as Lukasz Huminiecki and Peter Noy. These partnerships have further enriched his research and contributed to the advancement of his innovative projects.
Conclusion
Roy Bicknell's contributions to the field of angiogenesis inhibition through his patents and collaborations highlight his role as a leading inventor in biomedical research. His work continues to pave the way for new therapeutic approaches.